论文部分内容阅读
Lung cancer has become the first lethal disease among malignant tumors in China recent years.The Chinese morbidity of lung cancer increased by 26.9% every yearwhat results in more than 600,000 deathsandat least 80% cases are NSCLC.Traditional diagnosis like pathological morphology,biopsy, could not fulfill with growing requirement of early stage detection which may elevates a general 5 year survival from 15% (detection in advanced stage to 70%).Although, the low-dose spiral CT (LDCT) screening test is recommended especially by USPSTF, as common tool for early stage detection, it cannot overcome the shortcoming of the extremely high false positive rate.Nowadays non-invasive approaches that can help diagnose early stage of lung cancer are also necessary for distinguishing between benign nodules from malignant nodules.Based on the current situation, our diagnostics imported a so called Target FISH Lung Cancer Detection (LCD) Test which wasdeveloped byBioView company in Israel.This developed novel non-invasive diagnostic test aids in identification of subjects with lung cancer and utilizes BioView's patented Target-FISH technology to detect genetic changes in bronchial epithelial cells using sputum sample from subjects with pulmonary nodules.The test employstwo FISH probes, located at 3p22.1 and 10q22.3, which were discovered to have genetic abnormalities in malignant bronchial epithelial cells in brush and sputum of NSCLC.This technologyproduces a highly sensitive non-invasive test that enables the detection of lung cancer in its early stages.In proof of concept study (unpublished results), induced sputum samples from lung cancer patients showed significantly (p=0.001) higher level of genetic abnormalities compared to healthy smokers and non-smokers subjects (13.96% and 5.12%,respectively).Accuracy of test device was very high with sensitivity of >90% and specificity of >80%.A performance of BioView LCD Test was held at KindStar laboratory in Wuhan in 2013.Induced sputum samples were collected from 29 healthy subjects and from 9 symptomatic subjects suspected for lung cancer that were scheduled for a lung biopsy procedure at Tongji Hospital, Wuhan,China.The results were highly correlated to the subject's clinical status, lung cancer vs.non-cancerous (sensitivity 100%, specificity 96.6%).This study paved the novel way for Chinese early detection market of lung cancer in the future.